Your browser doesn't support javascript.
loading
Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization.
Xiong, Danyang; Zhao, Xiaoyu; Luo, Song; Cong, Yalong; Zhang, John Z H; Duan, Lili.
Afiliación
  • Xiong D; School of Physics and Electronics, Shandong Normal University, Jinan 250014, China.
  • Zhao X; School of Physics and Electronics, Shandong Normal University, Jinan 250014, China.
  • Luo S; School of Physics and Electronics, Shandong Normal University, Jinan 250014, China.
  • Cong Y; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • Zhang JZH; Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • Duan L; Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
J Phys Chem Lett ; 13(26): 6064-6073, 2022 Jul 07.
Article en En | MEDLINE | ID: mdl-35758899
ABSTRACT
Multiple-site mutated SARS-CoV-2 Delta and Omicron variants may trigger immune escape against existing monoclonal antibodies. Here, molecular dynamics simulations combined with the interaction entropy method reveal the escape mechanism of Delta/Omicron variants to Bamlanivimab/Etesevimab. The result shows the significantly reduced binding affinity of the Omicron variant for both antibodies, due to the introduction of positively charged residues that greatly weaken their electrostatic interactions. Meanwhile, significant structural deflection induces fewer atomic contacts and an unstable binding mode. As for the Delta variant, the reduced binding affinity for Bamlanivimab is owing to the alienation of the receptor-binding domain to the main part of this antibody, and the binding mode of the Delta variant to Etesevimab is similar to that of the wild type, suggesting that Etesevimab could still be effective against the Delta variant. We hope this work will provide timely theoretical insights into developing antibodies to prevalent and possible future variants of SARS-CoV-2.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: Glicoproteína de la Espiga del Coronavirus / COVID-19 Límite: Humans Idioma: En Revista: J Phys Chem Lett Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: Glicoproteína de la Espiga del Coronavirus / COVID-19 Límite: Humans Idioma: En Revista: J Phys Chem Lett Año: 2022 Tipo del documento: Article País de afiliación: China
...